A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or isoniazid.
Patients must have:
CD4 count 50 - 500 cells/mm3.
Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6 months use of another anti-HIV therapy other than d4T or any protease inhibitor.
No active opportunistic infection or visceral Kaposi's sarcoma.
Patients with hemophilia may be enrolled at discretion of investigator.
Patients with the following symptoms or conditions are excluded:
Antiretrovirals other than specified in protocol.
Chronic therapy for an active opportunistic infection.
Any prior protease inhibitor or d4T.
Any nucleoside analogs within 2 weeks prior to study entry.
Investigational agents or immunomodulators within 30 days prior to study entry.
More than 6 months of prior AZT unless intolerant, in which case more than 6 months of another anti-HIV therapy (other than protease inhibitors or d4T).